Suppr超能文献

巨噬细胞白细胞介素-10通过抑制肿瘤内树突状细胞中白细胞介素-12的表达来阻断CD8 + T细胞依赖的化疗反应。

Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells.

作者信息

Ruffell Brian, Chang-Strachan Debbie, Chan Vivien, Rosenbusch Alexander, Ho Christine M T, Pryer Nancy, Daniel Dylan, Hwang E Shelley, Rugo Hope S, Coussens Lisa M

机构信息

Department of Cell, Developmental & Cancer Biology and Knight Cancer Institute, Oregon Health & Science University, Portland, OR 97239, USA.

Novartis Institutes for Biomedical Research, Emeryville, CA 94608, USA.

出版信息

Cancer Cell. 2014 Nov 10;26(5):623-37. doi: 10.1016/j.ccell.2014.09.006. Epub 2014 Oct 16.

Abstract

Blockade of colony-stimulating factor-1 (CSF-1) limits macrophage infiltration and improves response of mammary carcinomas to chemotherapy. Herein we identify interleukin (IL)-10 expression by macrophages as the critical mediator of this phenotype. Infiltrating macrophages were the primary source of IL-10 within tumors, and therapeutic blockade of IL-10 receptor (IL-10R) was equivalent to CSF-1 neutralization in enhancing primary tumor response to paclitaxel and carboplatin. Improved response to chemotherapy was CD8(+) T cell-dependent, but IL-10 did not directly suppress CD8(+) T cells or alter macrophage polarization. Instead, IL-10R blockade increased intratumoral dendritic cell expression of IL-12, which was necessary for improved outcomes. In human breast cancer, expression of IL12A and cytotoxic effector molecules were predictive of pathological complete response rates to paclitaxel.

摘要

阻断集落刺激因子-1(CSF-1)可限制巨噬细胞浸润,并改善乳腺癌对化疗的反应。在此,我们确定巨噬细胞表达的白细胞介素(IL)-10是这种表型的关键介质。浸润性巨噬细胞是肿瘤内IL-10的主要来源,在增强原发性肿瘤对紫杉醇和卡铂的反应方面,对IL-10受体(IL-10R)的治疗性阻断等同于CSF-1中和。化疗反应的改善依赖于CD8(+) T细胞,但IL-10并不直接抑制CD8(+) T细胞或改变巨噬细胞极化。相反,阻断IL-10R可增加肿瘤内树突状细胞IL-12的表达,这是改善预后所必需的。在人类乳腺癌中,IL12A和细胞毒性效应分子的表达可预测对紫杉醇的病理完全缓解率。

相似文献

1
2
Macrophage-produced IL-10 limits the chemotherapy efficacy in breast cancer.
J Zhejiang Univ Sci B. 2015 Jan;16(1):44-5. doi: 10.1631/jzus.B1400352.
3
CD103+ dendritic cells producing interleukin-12 in anticancer immunosurveillance.
Cancer Cell. 2014 Nov 10;26(5):591-3. doi: 10.1016/j.ccell.2014.10.008.
4
Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy.
Cancer Discov. 2011 Jun;1(1):54-67. doi: 10.1158/2159-8274.CD-10-0028. Epub 2011 Jun 1.
5
Intratumoral delivery of encapsulated IL-12, IL-18 and TNF-alpha in a model of metastatic breast cancer.
Breast Cancer Res Treat. 2010 Jul;122(2):325-36. doi: 10.1007/s10549-009-0570-3. Epub 2009 Oct 3.
8
CD44high memory CD8 T cells synergize with CpG DNA to activate dendritic cell IL-12p70 production.
J Immunol. 2009 Jul 1;183(1):41-50. doi: 10.4049/jimmunol.0803473. Epub 2009 Jun 17.
9
Macrophage- and dendritic-cell-derived interleukin-15 receptor alpha supports homeostasis of distinct CD8+ T cell subsets.
Immunity. 2009 Nov 20;31(5):811-22. doi: 10.1016/j.immuni.2009.09.017. Epub 2009 Nov 12.
10
Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors.
Cancer Res. 2011 Jul 15;71(14):4809-20. doi: 10.1158/0008-5472.CAN-11-0753. Epub 2011 Jun 6.

引用本文的文献

1
Dual roles of innate immune cells and cytokines in shaping the breast cancer microenvironment.
Front Immunol. 2025 Aug 20;16:1654947. doi: 10.3389/fimmu.2025.1654947. eCollection 2025.
2
Mechanisms and clinical advancements of cell-based immunotherapies in non-small cell lung cancer: an integrated perspective.
Front Immunol. 2025 Aug 19;16:1633100. doi: 10.3389/fimmu.2025.1633100. eCollection 2025.
5
Distinct immune microenvironment of venous tumor thrombus in hepatocellular carcinoma at single-cell resolution.
Hepatology. 2025 Sep 1;82(3):566-581. doi: 10.1097/HEP.0000000000001182. Epub 2024 Dec 10.
6
An oral heme oxygenase inhibitor targets immunosuppressive perivascular macrophages in preclinical models of cancer.
Sci Transl Med. 2025 Aug 6;17(810):eads3085. doi: 10.1126/scitranslmed.ads3085.
7
Patient-derived ovarian cancer models demonstrate the influence of tumor-associated macrophages on therapeutic response.
Oncoimmunology. 2025 Dec;14(1):2537710. doi: 10.1080/2162402X.2025.2537710. Epub 2025 Aug 1.
8
Efficacy analysis of targeted P53 therapy in solid tumors.
Med Oncol. 2025 Jul 22;42(8):360. doi: 10.1007/s12032-025-02930-y.
9
Rewriting the dendritic cell code in cancer-from subset identity to immunotherapeutic design.
FEBS Lett. 2025 Jul;599(14):2060-2083. doi: 10.1002/1873-3468.70108. Epub 2025 Jul 16.
10
Chemoresistant tumor cell secretome potentiates immune suppression in triple negative breast cancer.
Breast Cancer Res. 2025 Jul 14;27(1):131. doi: 10.1186/s13058-025-02082-x.

本文引用的文献

1
Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy.
Cancer Cell. 2014 Jun 16;25(6):846-59. doi: 10.1016/j.ccr.2014.05.016. Epub 2014 Jun 2.
3
Therapeutic use of dendritic cells to promote the extranodal priming of anti-tumor immunity.
Front Immunol. 2013 Nov 29;4:388. doi: 10.3389/fimmu.2013.00388.
4
Inhibition of CSF-1 receptor improves the antitumor efficacy of adoptive cell transfer immunotherapy.
Cancer Res. 2014 Jan 1;74(1):153-161. doi: 10.1158/0008-5472.CAN-13-1816. Epub 2013 Nov 18.
5
Tumor hypoxia does not drive differentiation of tumor-associated macrophages but rather fine-tunes the M2-like macrophage population.
Cancer Res. 2014 Jan 1;74(1):24-30. doi: 10.1158/0008-5472.CAN-13-1196. Epub 2013 Nov 12.
6
Interferon-dependent IL-10 production by Tregs limits tumor Th17 inflammation.
J Clin Invest. 2013 Nov;123(11):4859-74. doi: 10.1172/JCI65180.
7
Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer.
Immunity. 2013 Oct 17;39(4):782-95. doi: 10.1016/j.immuni.2013.10.003.
8
CSF-1R inhibition alters macrophage polarization and blocks glioma progression.
Nat Med. 2013 Oct;19(10):1264-72. doi: 10.1038/nm.3337. Epub 2013 Sep 22.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验